A most excellent memo - I wasn't aware of that Nevada Lawyer interview - she indeed learned nothing about V during the trial. Can I make one suggestion? I would work "icosapent ethyl" into Section C, to further distinguish that V is entirely different from "fish oil" by chemical composition - fish oil in it's naturally occurring state is in the triglyceride form, while V undergoes processing that creates a molecule that doesn't occur in nature, the ethyl ester form of EPA, icosapent ethyl (which automatically defines it as a drug by FDA regs). Will be interesting to see how AMRN responds to your submission and whether they really should work it into the appeal somehow - various legal experts like Markman have stated that AMRN should be laser focused on one or two issues, and something like this might just be a distraction.